NUTLEY, N.J.

纽特利，新泽西州

,

，

April 9, 2026

2026年4月9日

/PRNewswire/ -- Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI

/PRNewswire/ -- 卫材公司今天宣布，公司将展示lecanemab（通用名，商品名：LEQEMBI）的最新研究结果

®

®

), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 2026 American Academy of Neurology (AAN) Annual Meeting from April 18-22 in Chicago and online. The lecanemab data and additional research findings from Eisai's neurology portfolio will be featured in 14 presentations, including four oral presentations.

），卫材的抗淀粉样蛋白β（Aβ）原纤维抗体，用于治疗阿尔茨海默病（AD），将于2026年4月18日至22日在芝加哥及线上举行的美国神经病学学会（AAN）年会上展示。Lecanemab的数据及卫材神经科产品组合中的其他研究发现将在14个报告中展示，其中包括四个口头报告。

Eisai will also host an Industry Therapeutic Update..

卫材还将举办行业治疗更新会议。

Oral and Poster Presentations

口头报告和海报展示

Oral presentations during the 'New Perspectives on Alzheimer's Therapeutics' scientific platform session highlight the breadth of lecanemab research, including mechanistic and biomarker insights, advances in treatment delivery, and long-term clinical outcomes. Poster presentations further underscore how lecanemab research and real-world evidence, particularly from geriatric practice settings, are shaping evolving care pathways and supporting a more standardized framework for diagnosing and treating early AD..

在“阿尔茨海默病治疗新视角”科学平台会议的口头报告中，重点展示了lecanemab研究的广泛性，包括机制和生物标志物的见解、治疗递送的进展以及长期临床结果。海报展示进一步强调了lecanemab研究和真实世界证据，特别是来自老年医学实践环境的证据，如何塑造不断发展的护理路径，并支持建立一个更标准化的早期阿尔茨海默病诊断和治疗框架。

Eisai Industry Therapeutic Update – Smoldering Alzheimer's Disease: The Ongoing Benefit of Addressing Multiple Pathologies

卫材行业治疗更新——隐匿性阿尔茨海默病：应对多种病理的持续益处

Eisai is sponsoring a two-part symposium on Monday, April 20 from 6:00-8:00 PM CDT featuring five leading global experts in the field of AD. The first session will focus on the newly emerging concept of smoldering AD, a slow-burning process that begins decades before clinical symptoms. The second session will explore how anti-amyloid therapy addresses multiple aspects of AD, including and extending beyond plaque removal..

卫材公司正在赞助一个两部分的研讨会，时间为4月20日星期一晚上6:00-8:00（中部夏令时），届时将有五位阿尔茨海默病（AD）领域的全球顶尖专家出席。第一部分将聚焦于新兴的“潜伏性AD”概念，这是一种在临床症状出现前数十年就开始缓慢发展的过程。第二部分将探讨抗淀粉样蛋白疗法如何作用于AD的多个方面，包括但不限于斑块清除。

The symposium aims to equip healthcare professionals with practical, evidence-based insights to support earlier detection of AD, confident interpretation of biomarkers across the disease continuum, and stronger patient and care partner conversations. The program draws on clinical trial data, long-term outcomes, and real-world evidence to translate emerging science into clinical practice..

该研讨会旨在为医疗保健专业人员提供实用的、基于证据的见解，以支持更早地检测阿尔茨海默病（AD），在疾病全过程中自信地解读生物标志物，并加强患者与护理伙伴的沟通。该项目依托临床试验数据、长期结果以及真实世界证据，将新兴科学转化为临床实践。

AAN 2026 Presentations Relating to Eisai's Key Compounds and Research

2026年AAN与卫材关键化合物和研究相关的演讲

Oral Presentations

口头报告

Asset / Topic, Session, Presentation Time (CDT)

资产/主题，会议，演示时间（CDT）

Presentation Title

演示标题

Lecanemab

勒卡奈单抗

New Perspectives on Alzheimer's Therapeutics

阿尔茨海默病治疗的新视角

Sunday, April 19, 1:24–1:36 PM

4月19日，星期日，下午1:24–1:36

The Effects of Lecanemab Treatment on Soluble CSF Aß Protofibrils (PF) in Clarity AD

Lecanemab治疗对Clarity AD中可溶性脑脊液Aß原纤维（PF）的影响

Lecanemab

雷卡内单抗

New Perspectives on Alzheimer's Therapeutics

阿尔茨海默病治疗的新视角

Sunday, April 19, 1:36–1:48 PM

4月19日，星期日，下午1点36分至1点48分

Clinical Profile for Lecanemab Subcutaneous Formulation for Treatment Initiation and Maintenance in Early Alzheimer's Disease (AD)

早期阿尔茨海默病（AD）治疗启动与维持的Lecanemab皮下注射制剂的临床概况

Lecanemab

雷卡奈单抗

New Perspectives on Alzheimer's Therapeutics

阿尔茨海默病治疗的新视角

Sunday, April 19, 1:48–2:00 PM

4月19日，星期日，下午1:48–2:00

The Lecanemab Clarity AD Open-label Extension in Early Alzheimer's Disease: Initial Findings from the 48-month Analysis

早期阿尔茨海默病的Lecanemab Clarity AD开放标签扩展研究：来自48个月分析的初步发现

Lecanemab

勒卡内单抗

New Perspectives on Alzheimer's Therapeutics

阿尔茨海默病治疗的新视角

Sunday, April 19, 2:00–2:12 PM

4月19日，星期日，下午2:00–2:12

Estimating the 10-Year Time-savings Benefits of Lecanemab Treatment

估计Lecanemab治疗的10年时间节省效益

Poster Presentations

海报展示

Lecanemab

Lecanemab

Poster Session Date & Time (CDT)

海报会议日期与时间（CDT）

Abstract Title

摘要标题

Poster Session 1

海报会议 1

Sunday, April 19, 8:00–9:00 AM

4月19日，星期日，早上8:00–9:00

Baseline Characteristics and Preliminary Safety from a Multicenter, Safety Surveillance Study of Lecanemab Treatment for Alzheimer's Disease in Real-world Clinical Practice Using Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) Registry

使用阿尔茨海默病治疗与诊断网络（ALZ-NET）注册库的真实世界临床实践中Lecanemab治疗阿尔茨海默病的多中心安全性监测研究的基线特征与初步安全性

Poster Session 1

海报会议 1

Sunday, April 19, 8:00–9:00 AM

4月19日，星期日，早上8:00–9:00

Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance – Estimating Accumulating or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials

在治疗持续超过斑块清除后，益处继续累积——评估CLARITY AD和TRAILBLAZER-ALZ2试验中累积或持续的治疗效益

Poster Session 2

海报会议 2

Sunday, April 19, 11:45 AM–12:45 PM

4月19日，星期日，上午11点45分至下午12点45分

Long-term Benefit of Lecanemab in Patients with Low Baseline Amyloid: Estimation of Time Saved

低基线淀粉样蛋白患者使用Lecanemab的长期益处：节省时间的估算

Poster Session 2

海报会议 2

Sunday, April 19, 11:45 AM–12:45 PM

4月19日，星期日，上午11点45分至下午12点45分

Lecanemab Real-world Treatment Outcomes from a Geriatric Medicine Clinical Practice: A Retrospective Dementia Clinic Case Series Review in Early Alzheimer's Disease

Lecanemab在老年医学临床实践中的真实世界治疗结果：早期阿尔茨海默病痴呆门诊病例系列回顾

Poster Session 2

海报会议 2

Sunday, April 19, 11:45 AM–12:45 PM

4月19日，星期日，上午11点45分至下午12点45分

Real-world Clinical, Safety and Patient-reported Outcomes of Treatment with Lecanemab in a New England Alzheimer's Disease Center

新英格兰阿尔茨海默病中心使用Lecanemab治疗的真实世界临床、安全性和患者报告结果

Diagnosis & Treatment in Early Alzheimer's Disease

早期阿尔茨海默病的诊断与治疗

Poster Session Date & Time (CDT)

海报会议日期与时间（CDT）

Abstract Title

摘要标题

Poster Session 1

海报会议 1

Sunday, April 19, 8:00–9:00 AM

4月19日，星期日，早上8:00–9:00

Delphi Consensus for Implementation of Anti-Amyloid mAbs  in Private Practice Neurology: Recommendations from Experienced Providers

德尔菲共识：在私人执业神经科中实施抗淀粉样蛋白单克隆抗体的建议：来自经验丰富的提供者的建议

Poster Session 7

海报会议 7

Tuesday, April 21, 8:00–9:00 AM

4月21日，星期二，早上8:00–9:00

Understanding How Patients with Mild Cognitive Impairment and Alzheimer's Disease Present at First Encounter: Toward a Standardized Framework for Therapy Eligibility

了解轻度认知障碍和阿尔茨海默病患者初次就诊时的表现：迈向治疗资格的标准化框架

Lemborexant

莱博雷生

Poster Session Date & Time (CDT)

海报会议日期与时间（CDT）

Abstract Title

摘要标题

Poster Session 6

海报会议 6

Monday, April 20 5:00–6:00 PM

4月20日星期一，下午5:00–6:00

Interpreting Adverse Events of Somnolence With Lemborexant in Clinical Trials

在临床试验中解读Lemborexant的嗜睡不良事件

Poster Session 11

海报会议 11

Wednesday, April 22, 11:45 AM–12:45 PM

4月22日星期三，上午11点45分至下午12点45分

Does Treatment for Insomnia Improve Sleep State Misperception?

失眠治疗是否能改善睡眠状态的误判？

E2086

E2086

Poster Session Date & Time (CDT)

海报会议日期与时间（CDT）

Abstract Title

摘要标题

Poster Session 6

海报会议 6

Monday, April 20, 5:00–6:00 PM

4月20日星期一，下午5:00–6:00

E2086, a Selective Orexin Receptor Two Agonist: Study for Promoting Wakefulness in Patients with Narcolepsy Type One

E2086，一种选择性食欲素受体2激动剂：用于促进1型嗜睡症患者清醒的研究

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

卫材在全球范围内主导lecanemab的开发和监管提交工作，卫材和渤健共同商业化和推广该产品，卫材拥有最终决策权。

This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.

本发布稿讨论了正在开发中的药物的试验性用途，不旨在传达有关有效性和安全性的结论。不能保证此类试验性药物将成功完成临床开发或获得卫生部门的批准。

MEDIA CONTACTS

媒体联系人

Public Relations Department,

公共关系部，

Eisai Co., Ltd.

卫材株式会社

+81-(0)3-3817-5120

+81-(0)3-3817-5120

Eisai Europe, Ltd.

卫材欧洲有限公司

(Europe, Australia, New Zealand and Russia)

（欧洲、澳大利亚、新西兰和俄罗斯）

EMEA Communications Department

欧洲、中东和非洲通信部

+44 (0) 7739-600-678

+44 (0) 7739-600-678

[email protected]

电子邮件地址

Eisai, Inc. (U.S.)

卫材公司（美国）

Julie Edelman

朱莉·埃德尔曼

+1-862-213-5915

+1-862-213-5915

Julie

朱莉

[email protected]

电子邮件地址

[Notes to editors]

[编辑须知]

1. About lecanemab (generic name, brand name: LEQEMBI

1. 关于lecanemab（通用名，商品名：LEQEMBI）

®

®

)

)

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Lecanemab 是卫材和 BioArctic 战略研究联盟的成果。它是一种人源化的免疫球蛋白伽马（IgG1）单克隆抗体，针对β淀粉样蛋白（Aβ）的聚集可溶性（原纤维）和不溶性形式。

Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 7 countries including the U.S., China, the UK, and others, and applications have been filed in 10 countries and regions.

Lecanemab 已在日本、美国、中国、欧洲、韩国、台湾和沙特阿拉伯等 53 个国家和地区获得批准，同时正在另外 6 个国家接受监管审查。在最初每两周一次、持续 18 个月的治疗阶段之后，包括美国、中国、英国等在内的 7 个国家已批准每四周一次的静脉注射（IV）维持剂量治疗，同时已在 10 个国家和地区提交了申请。

The U.S. FDA approved Eisai's Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026. The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted.

美国食品药品监督管理局（FDA）于2025年8月批准了卫材公司关于LEQEMBI IQLIK皮下维持剂量的生物制品许可申请（BLA）。2026年1月，起始治疗的补充生物制品许可申请（sBLA）获得受理，并被授予优先审查资格，处方药使用者费用法案（PDUFA）的行动日期为2026年5月24日。2025年11月，在日本提交了皮下注射制剂的申请。

In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the 'Commercial Insurance Innovative Drug List', recently introduced by the National Healthcare Security Administration (NHSA) of China..

2026年1月，皮下注射制剂的生物制品许可申请（BLA）在中国获得受理。2025年12月，Lecanemab（静脉注射）已被纳入中国国家医疗保障局（NHSA）最近发布的“商业保险创新药物清单”。

Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen.

自2020年7月以来，针对临床前阿尔茨海默病（AD）患者的III期临床研究（AHEAD 3-45）正在进行中。这些患者临床表现正常，但大脑中β淀粉样蛋白水平处于中等或升高状态。AHEAD 3-45是由阿尔茨海默病临床试验联盟与美国国家老龄化研究所（隶属于国立卫生研究院）、卫材（Eisai）和渤健（Biogen）合作开展的公私合作项目，该联盟为美国境内阿尔茨海默病及相关痴呆症的学术临床试验提供基础设施，由国家老龄化研究所资助。

Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy..

自2022年1月以来，由华盛顿大学圣路易斯分校医学院主导的显性遗传阿尔茨海默病网络试验单位（DIAN-TU）开展的针对显性遗传阿尔茨海默病（DIAD）的Tau NexGen临床研究正在进行中，并将lecanemab作为主要的抗淀粉样蛋白疗法。

2. About Protofibrils

2. 关于原纤维

Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.

原纤维被认为是导致AD脑损伤的原因之一，并被认为是最具毒性的可溶性Aβ形式，在这种渐进性、致衰弱状况相关的认知衰退中起主要作用。

1

1

Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells.

原纤维会导致大脑中的神经元损伤，这反过来可能通过多种机制对认知功能产生负面影响，不仅增加了不溶性Aβ斑块的形成，还加剧了对脑细胞膜以及在神经细胞之间或神经细胞与其他细胞之间传递信号的连接的直接损害。

It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction..

据信，减少原纤维的形成可能通过减轻大脑神经元损伤和认知功能障碍来阻止AD的进展。

2

2

3. About lemborexant (product name: DAYVIGO

3. 关于lemborexant（产品名称：DAYVIGO）

®

®

)

)

Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects.

Lemborexant是一种食欲素受体拮抗剂，是卫材公司自主研发的小分子化合物，通过竞争性结合两种食欲素受体亚型（食欲素受体1和2）来抑制食欲素神经传递。Lemborexant对食欲素受体的快速结合/解离动力学可能影响其在促进睡眠起始和维持方面的潜力，同时减少早晨残留效应。

It has been approved for the treatment of insomnia in more than 25 countries including Japan, the United States, China, Canada, Australia and countries in Asia and the Middle East..

它已获批准用于治疗失眠症，覆盖超过25个国家和地区，包括日本、美国、中国、加拿大、澳大利亚以及亚洲和中东国家。

4. About E2086

4. 关于E2086

E2086 is Eisai's in-house discovered novel selective orexin 2 receptor agonist. Nonclinical studies have demonstrated statistically significant increases in time spent awake and significant reductions in rates of cataplexy. Furthermore, in a Phase Ib clinical trial with patients with narcolepsy type 1, the agent demonstrated a statistically significant reduction in excessive daytime sleepiness compared to placebo or the existing drug (modafinil)..

E2086是卫材公司内部发现的一种新型选择性食欲素2受体激动剂。非临床研究已证明，其在清醒时间上显著增加，并显著降低了猝倒的发生率。此外，在针对1型嗜睡症患者的Ib期临床试验中，该药物与安慰剂或现有药物（莫达非尼）相比，表现出在减轻日间过度嗜睡方面的统计学显著效果。

3

3

In February 2026, it was designated as an orphan drug for narcolepsy by the Ministry of Health, Labour and Welfare in Japan.

2026年2月，它被日本厚生劳动省指定为治疗嗜睡症的孤儿药。

5. About the Collaboration between Eisai and Biogen for AD

5. 关于卫材和百健在AD方面的合作

Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority..

自2014年以来，卫材和渤健一直在合作开发和商业化阿尔茨海默病治疗药物。卫材在全球范围内主导LEQEMBI的开发和监管提交，两家公司共同商业化和推广该产品，卫材拥有最终决策权。

6. About the Collaboration between Eisai and BioArctic for AD

关于卫材和BioArctic在AD方面的合作

Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015..

自2005年以来，卫材和BioArctic就阿尔茨海默病（AD）治疗药物的开发和商业化进行了长期合作。根据2007年12月与BioArctic达成的协议，卫材获得了研究、开发、制造和销售lecanemab用于治疗AD的全球权利。关于lecanemab备用抗体的开发和商业化协议于2015年5月签署。

References

参考文献

Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers.

Amin L，Harris DA。Aβ受体特异性识别纤维末端和神经毒性寡聚体展示的分子特征。

Nat Commun

自然通讯

. 2021;12: 3451. doi:10.1038/s41467-021-23507-z.

. 2021;12: 3451. doi:10.1038/s41467-021-23507-z.

Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease.

小野K，辻M。β淀粉样蛋白的原纤维是阿尔茨海默病疾病修饰方法的重要靶点。

Int J Mol Sci.

国际分子科学杂志。

2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

2020；21（3）：952。doi：10.3390/ijms21030952。PMID：32023927；PMCID：PMC7037706。

Eisai Co., Ltd. E2086, A Selective Orexin Receptor-2 Agonist, Promotes Wakefulness in Patients with Narcolepsy Type-1. Presented at the World Sleep Congress, Singapore, 8 September 2025.

卫材株式会社 E2086，一种选择性食欲素受体-2激动剂，在1型嗜睡症患者中促进清醒。于2025年9月8日在新加坡世界睡眠大会上发表。

SOURCE Eisai Inc.

来源：卫材公司

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示